- Home
- CYCC
as 11-15-2024 4:00pm EST
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.
| Founded: | 1992 | Country: | United States |
| Employees: | N/A | City: | BERKELEY HEIGHTS |
| Market Cap: | 1.8M | IPO Year: | N/A |
| Target Price: | $11.00 | AVG Volume (30 days): | 3.7M |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -7.47 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.35 - $6.00 | Next Earning Date: | 11-12-2024 |
| Revenue: | $74,000 | Revenue Growth: | -80.98% |
| Revenue Growth (this year): | -89.56% | Revenue Growth (next year): | 16.28% |
Latest Cyclacel Pharmaceuticals Inc. News
CYCC Breaking Stock News: Dive into CYCC Ticker-Specific Updates for Smart Investing
Simply Wall St.
3 days ago
Cyclacel Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations
GlobeNewswire
4 days ago
Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds
GlobeNewswire
5 days ago
Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds
Zacks
6 days ago
Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q3 Loss
GlobeNewswire
6 days ago
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
GlobeNewswire
25 days ago
Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule
GlobeNewswire
a month ago
Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
GlobeNewswire
a month ago
Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
Compare CYCC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CYCC Cyclacel Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.